SCHEMBL22747626

SCHEMBL22747626

CCOC(=O)CCc1c(-c2ccccc2)[nH]c2cc(F)ccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 1/20 0.48
▸ TUBB4A P04350 1/20 0.48
▸ TUBB P07437 1/20 0.48
▸ TUBA3C P0DPH7 1/20 0.48
▸ TUBA1B P68363 1/20 0.48
▸ TUBA4A P68366 1/20 0.48
▸ TUBB4B P68371 1/20 0.48
▸ TUBB3 Q13509 1/20 0.48
▸ TUBB2A Q13885 1/20 0.48
▸ TUBB8 Q3ZCM7 1/20 0.48
▸ TUBA3E Q6PEY2 1/20 0.48
▸ TUBA1A Q71U36 1/20 0.48
▸ TUBA1C Q9BQE3 1/20 0.48
▸ TUBB6 Q9BUF5 1/20 0.48
▸ TUBB2B Q9BVA1 1/20 0.48
▸ TUBB1 Q9H4B7 1/20 0.48
▸ PPARG P37231 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22160189 0.85 GPR17 (0.57) TACR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL7230833 0.78 TSPO (0.54) TACR1PPARGKDM4EMEN1ALDH1A1
SCHEMBL22747625 0.77 TUBB4A (0.47) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL7238606 0.76 PPARG (0.55) TACR1PPARGKDM4EMEN1ALDH1A1
SCHEMBL26136119 0.76 PTPN1 (0.47) KDM4EMEN1ALDH1A1LMNAGAA
SCHEMBL9536890 0.76 LMNA (0.62) KDM4EMEN1ALDH1A1LMNAGAA
SCHEMBL10981215 0.76 CYP11B1 (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL14740022 0.76 GPR17 (0.61) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22118373 0.75 EGFR (0.65) TACR1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31404858 0.75 EGFR (0.65) TACR1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 — — US disclosed
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-08-31 — — US disclosed
US-11618746-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-04 — — US disclosed
US-20200377479-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmacéuticals Incorporated 2020-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271945-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, SAAL1 TACR1 4124/4885TUBB4A 1985/4885TUBB 1918/4885
US-11618746-B2 Inhibitors of APOL1 and methods of using same APOL1, APOB, NPC1L1 TACR1 4461/4885TUBB4A 2620/4885TUBB 2699/4885
US-20200377479-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, SAAL1, LOXL1 TACR1 4244/4885TUBB4A 2179/4885TUBB 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback